DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

Revlimid (lenalidomide) can cause side effects that range from mild to serious. More common side effects include nausea, fatigue, and anemia. If side effects from Revlimid become difficult to ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

Dr Reddy's share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to 'Buy' with a target of ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales last year.

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory ...

Tecvayli, alone or with Revlimid, showed robust efficacy in newly diagnosed multiple myeloma post-ASCT, achieving 100% MRD-negativity in all cohorts. Complete remission rates were highest in cohort 1, ...

Image source: Kaboompics.com from Pexels Revlimid (Lenalidomide) is an immunomodulatory medicine that can change the immune system to work more effectively and is a first line medication used to ...